ArticleScientific reports2025
Substantial co-trimoxazole resistant S. aureus nasal carriage despite low colonization among people living with HIV in Ethiopia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is the second cause of antimicrobial-resistance related deaths globally. In Sub-Saharan Africa, especially among People Living with HIV/AIDS (PLWHA), the risk associated with S. aureus colonization is estimated to be higher than the global average. In this region, co-trimoxazole prophylaxis therapy (CPT) has been given as HIV care package for decades. However, the effect on nasal colonization and resistance development has so far been scarcely studied. This study aims to determine the extent of co-trimoxazole-resistant S. aureus nasal carriage among PLWHA in relation to CPT use. A cross-sectional study was carried out. A total of 400 participants were enrolled randomly. Sociodemographic and clinical data were collected using a pre-structured questionnaire and case report form. Nasal swabs were collected and cultured on recommended culture media. An antimicrobial susceptibility test was performed using standard disc diffusion method. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline was followed in the interpretation of the AMR. Data were analyzed using chi-square test with a p-value below 0.05 cut-off. The nasal colonization rate of S. aureus was 13.3% (53/400) [95% C.I: (10.3, 16.9)], with 56.6% (30/53) of isolates being co-trimoxazole resistant. There is a difference in nasal carriage of co-trimoxazole sensitive S. aureus (COTSSA), co-trimoxazole-resistance S. aureus (COTRSA) and coagulase negative staphylococcus (CoNS) by CPT use (p = 0.0005). CD4 + count less than 350 cells/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.